Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Performances in N.Y.C. Advertisement Supported by Listen to recordings by Maria Dueñas and Daniil Trifonov, works by Thomas Adès and Tania León, and more. London Philharmonic Orchestra; Thomas Adès, ...

Performances in N.Y.C. Advertisement Supported by A holiday album that cuts through seasonal glut, a late collaboration by Jim McNeely and Helmut Lachenmann’s string quartets are among the highlights.

ATLANTA — Residents in a Buckhead senior community said they've endured two sleepless nights due to loud classical music and flashing blue lights coming from a mobile surveillance system installed in ...

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network. A structured, system-wide clinical pathway increased pediatric lipid ...

Meeting the needs of the community is one of North Idaho College President Nick Swayne’s main goals. So when he saw a growing trend toward classical education in the Inland Northwest with charter, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Lots of people are excited about the idea of using plants to help us draw down some of the excess carbon dioxide we’ve been pumping into the atmosphere. It would be nice to think that we could ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...